Search for a clinical study
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of Xmab541 in Advanced Solid Tumors
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. ...
FORAGER-1: a Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations
This is an open-label, multi-center, phase 1a/b study in participants with FGFR3-altered advanced solid tumors, including metastatic urothelial cancer (UC). The main purpose of this study is to learn more ...
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-Drug ...
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in patients with advanced or metastatic ...
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of Tng462 in Combination with Other Agents in Patients with ...
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with the following agents: RMC-6236, ...
1 a Randomized Phase Ii Study of Venetoclax and Hma-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed Flt3-Mutated Acute ...
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with ...
NF119: a Phase 2, Open-Label, Single Arm, Non-Controlled, Single-Stage Study to Evaluate the Safety and Effects of HLX-1502 in Patients with Plexiform Neurofibroma and Neurofibromatosis ...
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 ...
A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants with Isocitrate Dehydrogenase 1 (Idh1)-Mutant Glioma
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant ...
A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and ...
A Phase 1b/2 trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, ...
Phase 1 Imaging Study of 68Ga-R12961 in Advanced Solid Tumors
The goals of this study are:To describe the safety of 68Ga-R12961To describe preliminary imaging efficacy of 68Ga-R12961 in participants with advanced solid tumors.To compare 68Ga-R12961 positron emission tomography/computed tomography (PET/CT) ...
A Phase 1A/1B Study of the Pi3ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors
Phase 1a Dose Escalation/Cohort Expansion BBO-10203 Monotherapy Primary: To evaluate the safety and tolerability of BBO-10203, an inhibitor of the PI3Kα:RAS interaction, in subjects with locally advanced unresectable or metastatic (ie, ...